Bragar Eagel & Squire, P.C. is investigating potential claims against Myriad Genetics on behalf of Myriad stockholders. The investigation concerns whether Myriad violated federal securities laws or engaged in other unlawful business practices. On July 30, 2026, Myriad reported second-quarter revenue of approximately $190.7 million, down roughly 11% year-over-year and 7% to 8% below Wall Street consensus, and cut its full-year 2026 revenue guidance to $770-$790 million from approximately $860-$880 million. The firm encourages investors who suffered losses to contact partners Brandon Walker or Melissa Fortunato.
